Table 1.
Baseline demographics and disease characteristics
| Placebo (n = 14) | Infliximab (n = 12) | pc | |
|---|---|---|---|
| Demographics | |||
| Males, no. (%) | 13 (92.9) | 12 (100.0) | 1.000 |
| Age, years mean (SD) | 14.5 (2.7) | 15.0 (1.7) | 0.587 |
| Weight, kg mean (SD) | 55.2 (19.5) | 52.7 (14.5) | 0.718 |
| Body mass index, kg/m2 mean (SD) | 21.4 (5.1) | 19.7 (3.3) | 0.339 |
| Radiographic sacroiliitis a, no. (%) | 2 (14.3) | 2 (6.7) | 0.763 |
| Disease characteristics | |||
| Disease duration, years mean (SD) | 6.9 (3.5) | 6.4 (2.7) | 0.689 |
| HLA-B27, no. (%) | 13 (92.9) | 10 (90.9) | 0.859 |
| Family history of SpAb, no. (%) | 2 (14.3) | 1 (8.3) | 0.642 |
no. number, SD standard deviation
aRadiographic sacroiliitis if at least graded 2 or 3 bilateral or 3 unilateral
bFamily history of SpA refers to three cases with axSpA, one to nrSpA, and another to rSpA (AS)
cProbability values of true differences, utilizing parametric t-tests for continuous variables and non-parametric chi-squared tests for nominal variables